65 results
424B5
ANNX
Annexon Inc
5 Apr 24
Prospectus supplement for primary offering
4:07pm
in the clearance of pathogens and damaged cells. We have demonstrated robust target engagement in the body, brain and eye, and clinical proof of concept
8-K
EX-99.1
obzq6c1
4 Mar 24
Regulation FD Disclosure
5:25pm
424B5
is9vvqz hdx8u4p
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
h2uvm7
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
9a0u8w 7jk60
25 May 23
Other Events
6:08am
8-K
EX-99.1
qo8kv1 abaef
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am
8-K
EX-10.1
hepb2
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-99.2
5n6wl 7etabnw
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
z04xpir
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-99.1
bj8grkh4
7 Jun 22
Other Events
4:06pm